I'm not sure what to expect as far as detail from the presentation. I want to see it published in similar detail as what we saw with the 2a/CU patient publication in the near future. I really don't know what we'll hear tomorrow but certainly should expect much more detail than what we heard in May. My guess is the company knows it better give specifics that the market and BP will understand unlike what they were able to give us in early May that allowed the stock to be bashed. Obviously tomorrow isn't a "company presentation" but they could still give us data points during the 17 weeks that could give us a better idea of what we have than the single 12 week score and explain any score fluctuations over the course of the study.
If I were the company I would immediately have an additional investor's call to explain what shareholders should expect the rest of this year regarding FragileX, 2B extension, dosing trial, phase 3 status, etc. Answer whether they are in partnership discussions or when they think they'll need more funding. Keep things transparent.
Just outside the box thinking here, I would like to see Alkon sit down and do an interview in some fashion with some of the more knowledgeable posters here and answer specific questions about the science to make things more comprehensible to the masses. Everyone can't read dozens of research articles without having questions and wondering what avenues the company could take regarding the drug, how it works, commercial viability, etc. Tape the interview and put it on the website maybe? It's just a thought. Having informed shareholders would be a plus.
I realize that is more than you asked for, especially in regards to tomorrow. I'm sure the company has a plan, but we need to get the share price higher for any future funding/partnership reasons and sometimes just concentrating on the science may not be enough. A trend towards improve cognition is big news in the Alzheimer's world. We seem to have a story to tell or at least we'll know more about it tomorrow. JMHO
